AbbVie's Humira, used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has been the world's top-selling drug for years. Next year, it will face a patent cliff in the United States, but the drug has had a huge impact on lives and the bottom line of AbbVie.

Now, Eli Lilly (NYSE: LLY) and Bristol Myers Squibb (NYSE: BMY) have blockbuster drugs in the works that could also change lives and boost their companies' fortunes. Let's take a closer at them and what it could mean for these two companies.

Lilly's Mounjaro (tirzepatide), a once-weekly injection, received its first Food and Drug Administration (FDA) approval in May as a therapy to treat type 2 diabetes, but the therapy also has huge potential as a weight-loss drug. Mounjaro is unique because it is the first unimolecular dual GIP/GLP-1 receptor agonist. That's a mouthful, but what it means is that it can act the way two separate hormones do to control blood sugar levels.

Continue reading

Source Fool.com